Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART5803 in Anti-NMDAR Encephalitis and Psychiatric Disease
NCT07093333Phase 2Recruiting
- Sponsor
- Arialys Therapeutics
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ART5803 in anti-N-methyl D-aspartate receptor encephalitis, anti-NMDA receptor encephalitis, sponsored by Arialys Therapeutics. Started May 2026; status: recruiting.
02
Drugs
ART5803
03
Conditions
anti-N-methyl D-aspartate receptor encephalitisanti-NMDA receptor encephalitis
Beyond the preview
Go deeper on NCT07093333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07093333.